Novoste enlarges Beta-Cath brachytherapy trial:
This article was originally published in Clinica
Novoste is to enlarge the US trial of its Beta-Cath brachytherapy treatment for restenosis, after enrolling the 386 patients needed ahead of schedule. The Norcross, Georgia-based company now expects around 450 patients to take part in the eight-month Stents and Radiation Therapy (START) trial. Allowing time for patient follow-up and data analysis, Novoste expects to submit the data for US marketing approval of Beta-Cath to the FDA in the second quarter of 2000.
You may also be interested in...
Moderate growth at Bristol-Myers Squibb and Amgen moved the two companies into the top 10 pharma ranks, based on the most recent Scrip 100 rankings, while declining growth at Gilead and Teva moved those drug makers out.
Momenta Pharmaceuticals has agreed to pay $35.0m to settle claims that it manipulated generic approval processes in the US to shut competitor Amphastar out of the US enoxaparin market.